WO2006042857A3 - Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction - Google Patents

Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction Download PDF

Info

Publication number
WO2006042857A3
WO2006042857A3 PCT/EP2005/055388 EP2005055388W WO2006042857A3 WO 2006042857 A3 WO2006042857 A3 WO 2006042857A3 EP 2005055388 W EP2005055388 W EP 2005055388W WO 2006042857 A3 WO2006042857 A3 WO 2006042857A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
mequitazine
complex containing
interaction agent
complex
Prior art date
Application number
PCT/EP2005/055388
Other languages
English (en)
Other versions
WO2006042857A2 (fr
Inventor
Bernard Freiss
Hubert Lochard
Original Assignee
Pf Medicament
Bernard Freiss
Hubert Lochard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ555238A priority Critical patent/NZ555238A/en
Priority to BRPI0516233-5A priority patent/BRPI0516233A/pt
Priority to EP05801647A priority patent/EP1802348A2/fr
Priority to JP2007537271A priority patent/JP5157447B2/ja
Priority to KR1020077010998A priority patent/KR101273840B1/ko
Priority to CA2583783A priority patent/CA2583783C/fr
Priority to CN2005800358701A priority patent/CN101043908B/zh
Priority to AU2005296875A priority patent/AU2005296875B2/en
Application filed by Pf Medicament, Bernard Freiss, Hubert Lochard filed Critical Pf Medicament
Priority to MX2007004787A priority patent/MX2007004787A/es
Priority to US11/665,839 priority patent/US7749982B2/en
Publication of WO2006042857A2 publication Critical patent/WO2006042857A2/fr
Publication of WO2006042857A3 publication Critical patent/WO2006042857A3/fr
Priority to IL182412A priority patent/IL182412A/en
Priority to NO20072433A priority patent/NO20072433L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La présente invention concerne un complexe comprenant la méquitazine, une cyclodextrine et un agent d'interaction caractérisé en ce que le taux de solubilisation dans l'eau de la méquitazine complexée, mesuré pour un mélange à 2g/l de méquitazine dans l'eau à 35°C après 15 minutes d'agitation, est supérieur à 50% à pH 9. Elle concerne également un procédé de préparation de ce complexe et une composition pharmaceutique le comprenant.
PCT/EP2005/055388 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction WO2006042857A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN2005800358701A CN101043908B (zh) 2004-10-21 2005-10-19 含有美喹他嗪、环糊精和相互作用试剂的络合物
EP05801647A EP1802348A2 (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
JP2007537271A JP5157447B2 (ja) 2004-10-21 2005-10-19 メキタジンとシクロデキストリンと相互作用剤を含む複合体
KR1020077010998A KR101273840B1 (ko) 2004-10-21 2005-10-19 메퀴타진, 시클로덱스트린 및 상호 작용제를 포함하는복합체
CA2583783A CA2583783C (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
NZ555238A NZ555238A (en) 2004-10-21 2005-10-19 Complex containing mequitazine, a cyclodextrin and an interaction agent
AU2005296875A AU2005296875B2 (en) 2004-10-21 2005-10-19 Complex containing mequitazine, a cyclodextrin and an interaction agent
BRPI0516233-5A BRPI0516233A (pt) 2004-10-21 2005-10-19 complexo compreendendo a mequitazina, uma ciclodextrina, e um agente de interação, processo de preparação do mesmo, e, composição farmacêutica destinada a ser administrada por via oral
MX2007004787A MX2007004787A (es) 2004-10-21 2005-10-19 Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion.
US11/665,839 US7749982B2 (en) 2004-10-21 2005-10-19 Complex containing mequitazine, a cyclodextrin and an interaction agent
IL182412A IL182412A (en) 2004-10-21 2007-04-10 A mequitazine, cyclodextrin and l-arginine conjugate as an interaction mediator, a method of preparation, a pharmaceutical containing it and a conjugate for use as a drug
NO20072433A NO20072433L (no) 2004-10-21 2007-05-11 Kompleks som bestar av mekitazin, et syklodekstrin og et interaksjonsmiddel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0411202A FR2876910B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
FR0411202 2004-10-21

Publications (2)

Publication Number Publication Date
WO2006042857A2 WO2006042857A2 (fr) 2006-04-27
WO2006042857A3 true WO2006042857A3 (fr) 2006-07-27

Family

ID=34949969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/055388 WO2006042857A2 (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Country Status (18)

Country Link
US (1) US7749982B2 (fr)
EP (1) EP1802348A2 (fr)
JP (1) JP5157447B2 (fr)
KR (1) KR101273840B1 (fr)
CN (1) CN101043908B (fr)
AR (1) AR051593A1 (fr)
AU (1) AU2005296875B2 (fr)
BR (1) BRPI0516233A (fr)
CA (1) CA2583783C (fr)
FR (1) FR2876910B1 (fr)
IL (1) IL182412A (fr)
MX (1) MX2007004787A (fr)
NO (1) NO20072433L (fr)
NZ (1) NZ555238A (fr)
RU (1) RU2389491C2 (fr)
TW (1) TWI372759B (fr)
WO (1) WO2006042857A2 (fr)
ZA (1) ZA200703080B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
JP7029886B2 (ja) * 2017-04-28 2022-03-04 ロート製薬株式会社 医薬組成物及びその製造方法
KR20220085094A (ko) 2020-12-14 2022-06-22 메디케어제약 주식회사 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH023610A (ja) * 1988-06-13 1990-01-09 Toyo Jozo Co Ltd メキタジンの液状シロップ製剤
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
US5770596A (en) * 1995-12-06 1998-06-23 Laboratoire Chauvin S.A. Pharmaceutical compositions based on mequitazine
FR2788436A1 (fr) * 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
FR2815540A1 (fr) * 2000-10-19 2002-04-26 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) * 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830760A1 (fr) * 2001-10-12 2003-04-18 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250534A (fr) 1969-03-03 1971-10-20
FR2522660A1 (fr) * 1982-03-05 1983-09-09 Pharmuka Lab Isomere levogyre de la mequitazine, son procede de preparation et medicaments le contenant
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
TW262497B (en) * 1994-06-29 1995-11-11 Toshiba Co Ltd Washing machine
JPH10167954A (ja) * 1996-12-05 1998-06-23 Takada Seiyaku Kk メキタジン製剤
GB9800936D0 (en) * 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
DE69911159T2 (de) * 1999-01-06 2004-06-24 Técnimede-Sociedade Técnico-Medicinal, S.A. Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
PL2260871T3 (pl) * 2004-04-01 2013-10-31 Pf Medicament Kompleksy inkluzyjne zawierające piroksykam, cyklodekstrynę i argininę

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH023610A (ja) * 1988-06-13 1990-01-09 Toyo Jozo Co Ltd メキタジンの液状シロップ製剤
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
US5770596A (en) * 1995-12-06 1998-06-23 Laboratoire Chauvin S.A. Pharmaceutical compositions based on mequitazine
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
FR2788436A1 (fr) * 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
FR2815540A1 (fr) * 2000-10-19 2002-04-26 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) * 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830760A1 (fr) * 2001-10-12 2003-04-18 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1989, YLITALO P ET AL: "Serum levels and urinary excretion of mequitazine after a single oral dose.", XP002380504, Database accession no. NLM2576245 *
DATABASE WPI Section Ch Week 199007, Derwent World Patents Index; Class B02, AN 1990-049219, XP002380356 *
DATABASE WPI Section Ch Week 199312, Derwent World Patents Index; Class A96, AN 1993-098122, XP002375837 *
HEES VAN T ET AL: "APPLICATION OF SUPERCRITICAL CARBON DIOXIDE FOR THE PREPARATION OF A PIROXICAM-BETA-CYCLODEXTRIN INCLUSION COMPOUND", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 16, no. 12, 1999, pages 1864 - 1870, XP008006992, ISSN: 1043-6618 *
HEES VAN T ET AL: "APPLICATION OF SUPERCRITICAL CARBON DIOXIDE FOR THE PREPARATION OF DRUG-CYCLODEXTRIN INCLUSION COMPOUNDS", JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, KLUWER, DORDRECHT, NL, vol. 44, 2002, pages 271 - 274, XP008040794, ISSN: 1388-3127 *
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH. 1989, vol. 9, no. 5, 1989, pages 305 - 308, ISSN: 0251-1649 *
MURA P ET AL: "TERNARY SYSTEMS OF NAPROXEN WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN AND AMINOACIDS", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 260, no. 2, 24 July 2003 (2003-07-24), pages 293 - 302, XP008062550, ISSN: 0378-5173 *
RAJEWSKI R A ET AL: "PHARMACEUTICAL APPLICATIONS OF CYCLODEXTRINS. 2. IN VIVO DRUG DELIVERY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 85, no. 11, November 1996 (1996-11-01), pages 1142 - 1169, XP000629515, ISSN: 0022-3549 *
SWEETMAN S. C. (ED.): "Martindale: The Complete Drug Reference", 2002, PHARMACEUTICAL PRESS, ISBN: 0-85369-499-0, XP002380502 *
VEIGA, M. D. ET AL: "Dissolution studies of mequitazine in several dissolution media with sodium lauryl sulfate, Tween 20 and .beta.- cyclodextrin", WORLD MEETING ON PHARMACEUTICS, BIOPHARMACEUTICS AND PHARMACEUTICAL TECHNOLOGY, 1ST, BUDAPEST, MAY 9-11, 1995 , 625-6 PUBLISHER: APGI, CHATENAY MALABRY, FR. CODEN: 62JJAQ, 1995, XP008063854 *
VEIGA, MARIA-DOLORES ET AL: "Study of surfactants/.beta.- cyclodextrin interactions over mequitazine dissolution", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , 23(7), 721-725 CODEN: DDIPD8; ISSN: 0363-9045, 1997, XP008063858 *
YANG G S ET AL: "Enantioseparation of some clinically used drugs by capillary electrophoresis using sulfated [beta]-cyclodextrin as a chiral selector", CHROMATOGRAPHIA 2005 GERMANY, vol. 62, no. 7-8, October 2005 (2005-10-01), pages 441 - 445, XP002380501, ISSN: 0009-5893 *

Also Published As

Publication number Publication date
ZA200703080B (en) 2008-05-28
IL182412A0 (en) 2007-07-24
MX2007004787A (es) 2007-05-15
EP1802348A2 (fr) 2007-07-04
WO2006042857A2 (fr) 2006-04-27
US7749982B2 (en) 2010-07-06
BRPI0516233A (pt) 2008-08-26
AU2005296875A1 (en) 2006-04-27
US20070293454A1 (en) 2007-12-20
CN101043908A (zh) 2007-09-26
AU2005296875B2 (en) 2011-03-31
FR2876910B1 (fr) 2007-04-13
JP2008517035A (ja) 2008-05-22
TWI372759B (en) 2012-09-21
KR20070084223A (ko) 2007-08-24
CN101043908B (zh) 2011-11-16
CA2583783C (fr) 2013-05-21
JP5157447B2 (ja) 2013-03-06
RU2389491C2 (ru) 2010-05-20
AR051593A1 (es) 2007-01-24
NZ555238A (en) 2010-04-30
TW200621770A (en) 2006-07-01
CA2583783A1 (fr) 2006-04-27
FR2876910A1 (fr) 2006-04-28
NO20072433L (no) 2007-05-11
RU2007118640A (ru) 2008-11-27
IL182412A (en) 2015-02-26
KR101273840B1 (ko) 2013-06-11

Similar Documents

Publication Publication Date Title
WO2005084296A3 (fr) Composes tricycliques fusionnes en tant qu'inhibiteurs de 17beta-hydroxysteroide deshydrogenase 3
WO2006017246A3 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2002085903A3 (fr) Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique
TW200642694A (en) Anti-M-CSF antibody compositions
EP2260835A3 (fr) Composition destinée a inhiber le proteasome
WO2007027819A3 (fr) Compositions comprenant des agents pharmaceutiques peu solubles dans l'eau et des agents antimicrobiens
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
EP1827389A4 (fr) Compositions a nanoparticules a liberation prolongee et procedes d'utilisation
WO2007016352A3 (fr) Compositions orales liquides de losartan
IL226899A0 (en) Preparations and methods for modulating development@כלי@דם
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
WO2006078384A3 (fr) Derives de stilbene et leur utilisation pour fixer et imager des plaques amyloides
WO2007016388A3 (fr) Formulations liquides pour l'administration controlee des derives de benzisoxazole
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
ATE430559T1 (de) Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
WO2004113297A3 (fr) Derives de noyaux aza et utilisation de ceux-ci comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
WO2002041881A3 (fr) Kit a base de repinotan
WO2006042857A3 (fr) Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
WO2004073686A3 (fr) Solutions de medicaments dans du menthol
WO2004067564A3 (fr) Compositions contre l'antgene cancereux liv-1 et leurs utilisations
AU2003290511A8 (en) Compositions and methods for the intracellular delivery of antibodies
HK1093721A1 (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
WO2005062874A3 (fr) Composes et compositions pour l'administration d'agents actifs
WO2004073738A3 (fr) Composition destinee a etre administree a un organisme vivant et procede de marquage d'agents
BG108945A (en) FIELD OF APPLICATION FOR ANTIGEN-BINDING ACTIVITY OF IMMUNOGLOBULIN PREPARATIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2627/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 182412

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2583783

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007/03080

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2007537271

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11665839

Country of ref document: US

Ref document number: 200580035870.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004787

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2005801647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005801647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077010998

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005296875

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 555238

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007118640

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005296875

Country of ref document: AU

Date of ref document: 20051019

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005296875

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005801647

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11665839

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516233

Country of ref document: BR